[ALLHAT--remaining questions await answers].
Nilsson
Peter M
PM
Avdelningen för medicin, Universitetssjukhuset MAS, Malmö. Peter.Nilsson@medforsk.mas.lu.se
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D000075202:Contraindications; D004232:Diuretics; D017292:Doxazosin / Q000627:therapeutic use; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D015201:Meta-Analysis as Topic; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic; D049993:Sodium Chloride Symporter Inhibitors / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D000960:Hypolipidemic Agents; D049993:Sodium Chloride Symporter Inhibitors; D017292:Doxazosin